An editorial in the Journal of Nuclear Medicine (J Nucl Med. 2007 Mar;48(3):331. PMID: 17332606) argues that combination PET/MRI systems are the future and will supplant PET/CT:
In a number of ways, the path to PET/MRI has been reverse of that to PET/CT. The first PET/CT design emerged from industry–academia collaboration and was a prototype for human clinical use that eventually stimulated a commercial response and led to the development of PET/CT for imaging small animals. In contrast, PET/MRI began with the small-animal design and then, over a decade later, the first PET/MRI brain images were acquired on a dedicated prototype system, following an impressive industrial backing that far exceeded that of the early PET/CT developments.
A mere 2 y after the advent of commercial PET/CT, Johannes Czernin from UCLA, at the 2003 annual DGN meeting, commented that “PET/CT is a technical evolution that has led to a medical revolution.” Today, at the dawn of PET/MRI, it may be said that “PET/MRI is a medical evolution based on a technical revolution.” Although PET/CT appears to have replaced stand-alone PET for most oncologic indications, it is reasonable to assume that PET/MRI will be the preferred imaging option for neurologic and central nervous system indications. Without doubt, such dual-modality combinations are here to stay because they incorporate the diagnostic power of PET. Thus, PET/CT and PET/MRI, by virtue of their combined anatometabolic imaging, will lead to a “new-clear” medicine and the demise of “unclear” medicine.